
Onc Fellow @Hopkins_HemOnc via @OslerResidency + @VanderbiltMSTP • chemical biologist studying cell death and metabolism ⚗️⚡️
Baltimore, MD
Joined January 2012
- Tweets1K
- Following2.6K
- Followers1.1K
- Likes11.8K
Pinned Tweet
I’m excited to share my thesis work on the mechanism of action of the apoptolidins in leukemia, out today @nchembio. 1/n
nature.com/articles/s41589-0…
Ben Reisman retweeted
Protein immunogenicity is a major driver of drug failure in the clinic, a problem especially important in the age of generative AI when we can design de novo medicines with desired function.
Meet 🐐MESSI: a generative method for deimmunizing proteins with discrete diffusion. We reduce predicted MHC-II epitopes and experimentally validate retained or improved function in luciferases, PD-1 binders and uricases—an enzyme family used in FDA-approved therapies.💊
Watch the story below:
1/n 🧵
Ben Reisman retweeted
Excited to share our new publication in Nature Metabolism @NatMetabolism led by the fantastic @XingxiuPan, where we uncover an unexpected connection between reductive and oxidative stress. This study contains many exciting findings, and I will be highlighting different aspects of this work in a series of posts.
One of the central conclusions is that the NADPH/NADP+ ratio is a critically underappreciated parameter in mitochondrial dysfunction.
In this study we present SaNADK, a new xenotopic tool based on the S. aureus NAD kinase, which expands the cellular NADP(H) pool nearly six-fold! Most remarkably, together with the Peter Adams lab @AdamsBioAging, we found that increasing NADP(H) levels with SaNADK alone was sufficient to reverse age-associated hepatic transcriptomic signatures linked to metabolic dysfunction and inflammation as well as liver fibrosis highlighting the profound influence of NADP(H) metabolism on cellular aging.
We also uncovered an important aspect of mitochondrial bioenergetics. We found that NADH-driven reductive stress can cause excessive reduction of the coenzyme Q pool, creating a bottleneck for multiple coenzyme Q-dependent reactions. As a consequence, electron flow through CoQ-linked systems is impaired, including DHODH activity and de novo pyrimidine biosynthesis. These findings may help explain numerous observations in the literature that have long appeared counterintuitive, namely that mild mitochondrial complex I inhibition can sometimes be beneficial.
Here is the link to the study:
nature.com/articles/s42255-0…
Ben Reisman retweeted
Hi, we would like to introduce PAIR-Scan, an HLA-agnostic library-on-library screening technology that can identify reactive TCR–antigen pairs with optimal killing activity among up to ~100,000 possible candidate pairs in a single-step.
🧵(1/7)
biorxiv.org/content/10.64898…
Ven + HMA is remarkably effective against AML, but does HMA synergy depend on DNA hypomethylation? This letter argues no: synergy occurs at doses with minimal methylation changes, while a selective DNMT1 inhibitor that strongly demethylates DNA shows little synergy with Ven. 🤔
Excited to share our new work published in the British Journal of Haematology! 🧬
Great work led by Aida Selimović-Pašić and Lisa Haglund from the Nestor group @theNestorLab.
Read the paper 👇
onlinelibrary.wiley.com/doi/…
Congrats to the authors on this excellent and thought-provoking work! @theNestorLab @SandraHellberg5
onlinelibrary.wiley.com/doi/…
Ben Reisman retweeted
1/ We are thrilled to share our first @CellCellPress paper with the ATLAS team studying the role of antibodies, emphasizing autoantibodies in cancer (authors.elsevier.com/a/1nUSA…).
A very timely addition to the literature. Kudos to the authors for a well-documented SI that should help facilitate reproducibility. 🧑🍳🍔🇺🇸
Using burgers as a model system, a generative AI system rediscovers the classic Big Mac without explicit supervision and generates novel burgers optimized for deliciousness, sustainability, or nutrition, according to a paper in npj Science of Food. go.nature.com/3SU7JDQ
Ben Reisman retweeted
Looking for a postdoc? We are recruiting scientists who are finishing their PhD to study how metabolism shapes cancer progression, immunity, and therapeutic resistance. Recent highlight: our Nature paper on αKG tiny.cc/ur15101. Learn more at airdlab.com.
Ben Reisman retweeted
The timing could not be worse. At #ASCO2026, we saw #daraxonrasib double survival in #PDAC, a reminder that decades of NIH research investment are paying off. Yet federal research funding is being cut. The biggest victims won't be scientists... They'll be future patients
Ben Reisman retweeted
We used our HCC biobank to dip our toes into a controversial topic: circadian biology and immune checkpoint blockade
🔗 jitc.bmj.com/content/14/4/e0…
🧵A brief thread on the controversies and findings here...
@howardli123 @mnakazawa7
Ben Reisman retweeted
Our review dissecting the nuanced roles of mitochondria during cancer progression was just published in @AnnualReviews of Cancer Biology. This was driven by grad student David Sokolov, who wrote it in an approachable and entertaining style. Check it out:
annualreviews.org/content/jo…
Ben Reisman retweeted
RevMed just doubled overall survival in pancreatic cancer by using CypA-targeting molecular glues to potently drug oncogenic KRAS-ON, long deemed untouchable.
One funny thing is that probably the most fundamental insight for daraxonrasib sits in a PNAS paper that's been cited merely 84 times. This showed that molecular glues can coax an endogenous protein to wrap itself around utterly featureless surface. The other is a 2017 Cell Reports paper (just 68 citations) on how Sanglifehrin A can be used to repurpose CypA's surface. A lot of the game-changing stuff seems niche and unglamorous at first.
Greg Verdine is having a chembio Annus Mirabilis for his 2025-2026 streak: FOG-001, Daraxonrasib. He provided much of the foundational conceptual work behind taking out both Beta-catenin and KRAS*.
*of course many others contributed immensely, but let's give some credit where credit is due!
Ben Reisman retweeted
Now hiring a Postdoctoral Fellow in my lab at Vanderbilt. We study immunologic and metabolic dysfunction in human critical illness and sepsis.
See flyer in the next post for details and how to apply. Come join our Nashville team! 🩸🦠🧪🏥
#Postdoc #Immunology #Sepsis
Ben Reisman retweeted
In 1999, Tom Maniatis discovered something remarkable: neurons achieve self-avoidance via stochastic methylation of the protocadherin gene cluster.
We've just discovered this locus is an evolvable in-vivo barcode across the human tissues: biorxiv.org/cgi/content/shor… 🧵
Ben Reisman retweeted
1/11 Excited to share our study of polyamines in prostate cancer in @CR_AACR! We found that, in models of advanced PCa, supraphysiological androgens (SPA) drive production of polyamines that help the cancer survive. @PCF_Science @AACR @hopkinskimmel aacrjournals.org/cancerres/a…
Ben Reisman retweeted
Ethan Neumann, a 27-year-old PhD candidate in my lab, devoted himself to studying #fibrolamellar carcinoma, the cancer that claimed his life last week.
Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️
gofundme.com/f/ethan-neumann…
Ben Reisman retweeted
In @NatureMedicine: @marinabaretti & @MarkYarchoan @hopkinskimmel in an AYA cancer with unmet need:
A therapeutic peptide vaccine (FLC-vac) for fibrolamellar hepatocellular carcinoma: a phase 1 trial
nature.com/articles/s41591-0…
75% DCR, 25% PR, T cell exhaustion 👉🏽 resistance
Ben Reisman retweeted
Happy to get to share our work this year at ASH. Come by our oral on Sunday to learn how our novel F1 ATP synthase inhibitor kills AML cells and come by the poster on Monday to hear about why we think it effects AML metabolism very differently than other oxphos inhibitors #ASH25
Ben Reisman retweeted
I doubted studies claiming ICI infusion timing mattered (ICI half-life = weeks!). Afternoon patients surely differ in unmeasurable ways.
But now a randomized trial ➡️morning ICI does better… 🤔
asco.org/abstracts-presentat…
Ben Reisman retweeted
Today in @Nature we report a systematic strategy to activate & identify gene sets in plants. We identify 8 new genes from the yew tree's Taxol biosynthetic pathway, enabling us to engineer tobacco with 17- & 20-gene pathways to Taxol precursors baccatin III and dBz-deoxy-Taxol. a thread 1/x..
nature.com/articles/s41586-0…
With amazing coauthors @Sattely_lab @ctliu629 @fordycelab @Stanford_ChEMH @StanfordEng























